Meta-analysis of seven trials involving 30,000 patients showed that patients treated with the blood thinner Pradaxa (dabigatran) were slightly more likely to suffer from heart attack or acute coronary syndrome (either heart attack or angina) compared with patients who received two other commonly used anticoagulants, warfarin and enoxaparin. Only 0.79% of patients treated with either warfarin or enoxaparin had a heart attack or ACS compared with 1.19% of patients in the Pradaxa group.

Full Story:
HealthDay News

Related Summaries